Glaukos (NYSE:GKOS) is a medical technology company specializing in the development, manufacturing and commercialization of novel therapies for glaucoma and other chronic eye diseases. Founded in 1998 as NexGen Ophthalmics and rebranded in 2015, the company is headquartered in San Clemente, California. Glaukos is best known for pioneering micro-invasive glaucoma surgery (MIGS) devices that aim to reduce intraocular pressure with less tissue disruption than traditional glaucoma surgeries.
The company’s flagship products include the iStent family of implants—small, porous titanium micro-stents designed to be placed in the eye’s drainage system during cataract surgery to improve fluid outflow. Successive generations, such as the iStent inject and iStent infinite, offer multiple stents for greater anatomical coverage. Beyond MIGS, Glaukos markets the iDose TR intracameral implant that delivers sustained release of intraocular pressure-lowering medication, as well as the Avedro platform for corneal cross-linking to treat keratoconus and other corneal ectatic disorders.
Glaukos operates through a combination of direct sales forces and distribution partners, serving surgeons and patients across the United States, Europe, Asia-Pacific and Latin America. The company holds regulatory approvals in major markets, including FDA clearance in the U.S., CE marking in Europe and PMDA approval in Japan. Manufacturing facilities span North America and Latin America, supporting both product supply and ongoing research and development initiatives.
The leadership team at Glaukos brings together experienced executives in regulatory affairs, clinical research and global commercialization. Guided by a board that includes leading ophthalmologists and life-science professionals, the company continues to expand its product pipeline in glaucoma, corneal and retinal spaces while pursuing strategic collaborations to enhance its capabilities in drug delivery and surgical innovation.
